Zepbound News

Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire - Yahoo Finance

Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire Yahoo Finance

America Has a New GLP-1 Playbook - The Atlantic

America Has a New GLP-1 Playbook The Atlantic

Foundayo, Wegovy and how GLP-1 weight-loss pills compare to shots - USA Today

Foundayo, Wegovy and how GLP-1 weight-loss pills compare to shots USA Today

She Lost 100 Pounds on Zepbound. Then Her Insurance Cut Her Off - Business Insider

She Lost 100 Pounds on Zepbound. Then Her Insurance Cut Her Off Business Insider

When Weight-Loss Drugs Don’t Work - The New York Times

When Weight-Loss Drugs Don’t Work The New York Times

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market - CNBC

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market CNBC

US weight-loss drugmakers slash prices in fight to win customers - BBC

US weight-loss drugmakers slash prices in fight to win customers BBC

A new weight-loss pill is here. Here's how Foundayo compares to Wegovy, Zepbound, and other GLP-1 rivals. - Business Insider

A new weight-loss pill is here. Here's how Foundayo compares to Wegovy, Zepbound, and other GLP-1 rivals. Business Insider

Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect - Eli Lilly

Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect Eli Lilly

The new high dose of Wegovy costs less than Zepbound - MarketWatch

The new high dose of Wegovy costs less than Zepbound MarketWatch

Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire - The Motley Fool

Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire The Motley Fool

Genes May Predict How Much You’ll Lose on a Weight-Loss Drug - WSJ

Genes May Predict How Much You’ll Lose on a Weight-Loss Drug WSJ

Thinking About A GLP-1 Drug? Your Genetics Might Determine How Well You'll Fare - U.S. News & World Report

Thinking About A GLP-1 Drug? Your Genetics Might Determine How Well You'll Fare U.S. News & World Report

Growth vs. Stability: Lilly and J&J's 2026 Investment Face-Off - TradingView — Track All Markets

Growth vs. Stability: Lilly and J&J's 2026 Investment Face-Off TradingView — Track All Markets

Publix Pharmacy provides access to savings on GLP-1 Zepbound multi-dose KwikPen - Publix

Publix Pharmacy provides access to savings on GLP-1 Zepbound multi-dose KwikPen Publix

Eli Lilly launches Zepbound KwikPen on Ro - MSN

Eli Lilly launches Zepbound KwikPen on Ro MSN

Multi-Dose KwikPen Now Available for Zepbound Administration - Gastroenterology Advisor

Multi-Dose KwikPen Now Available for Zepbound Administration Gastroenterology Advisor

GoodRx and Eli Lilly Partner to Expand Access to Foundayo and Zepbound KwikPen - Pharmaceutical Commerce

GoodRx and Eli Lilly Partner to Expand Access to Foundayo and Zepbound KwikPen Pharmaceutical Commerce

Eli Lilly's Weight Loss Portfolio: Zepbound and Retatrutide Strategy - News and Statistics - IndexBox

Eli Lilly's Weight Loss Portfolio: Zepbound and Retatrutide Strategy - News and Statistics IndexBox

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen - CNBC

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen CNBC

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen Eli Lilly

Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site - CNBC

Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site CNBC

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight - Eli Lilly

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight Eli Lilly

Tirzepatide Injections for Sleep Apnea - GoodRx

Tirzepatide Injections for Sleep Apnea GoodRx

New GLP-1 weight-loss drugs are coming—and they’re stronger than Wegovy and Zepbound - Scientific American

New GLP-1 weight-loss drugs are coming—and they’re stronger than Wegovy and Zepbound Scientific American

Human Resources — Benefits shares four updates about prescription plan - Purdue University

Human Resources — Benefits shares four updates about prescription plan Purdue University

White House strikes deals for lower prices on obesity drugs - NPR

White House strikes deals for lower prices on obesity drugs NPR

Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook - Yahoo Finance

Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook Yahoo Finance

GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide - Business Wire

GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide Business Wire

Zepbound vs. Wegovy: Which Weight Loss Treatment Comes Out on Top? - Everyday Health

Zepbound vs. Wegovy: Which Weight Loss Treatment Comes Out on Top? Everyday Health

Zepbound Blindness Lawsuit [2026 Update] - robertkinglawfirm.com

Zepbound Blindness Lawsuit [2026 Update] robertkinglawfirm.com

Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection' - Eli Lilly

Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection' Eli Lilly

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight - Eli Lilly

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight Eli Lilly